BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment

BRISTOL MYERS SQUIBB CO

Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.
Net Sales Payment to CVR holders: approximately $4,526,082, payable by March 7, 2022.
Per CVR payment: approx $0.104592, based on record date March 6, 2022.
Payment stems from CVRs assumed in 2019 Celgene acquisition under the CVR Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.